LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Listă Acțiuni・Sana Biotechnology Inc

Sana Biotechnology Inc

Închisă

SectorSănătate

3.05 0.33

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.01

Maxim

3.22

Indicatori cheie
By Trading Economics
Venit	12M -47M
EPS	-0.171
Angajați	142
EBITDA	23M -35M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+184.59% upside

Dividende
By Dow Jones
Următoarele câștiguri	7 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-115M 846M
Deschiderea anterioară	2.72
Închiderea anterioară	3.05

Sentimentul știrilor

By Acuity

25%

75%

49 / 344 Clasament în Healthcare

Sana Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 mai 2026, 16:52 UTC

Evenimente importante

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mai 2026, 23:57 UTC

Câștiguri

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mai 2026, 23:57 UTC

Câștiguri

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mai 2026, 21:54 UTC

Câștiguri

Webco Industries 3Q EPS $11.61 >WEBC

26 mai 2026, 21:54 UTC

Câștiguri

Webco Industries 3Q Sales $179.6M >WEBC

26 mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 mai 2026, 20:58 UTC

Achiziții, Fuziuni, Preluări

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Auto & Transport Roundup: Market Talk

26 mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparație

Modificare preț

Sana Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

184.59% sus

Prognoză pe 12 luni

Medie 8.68 USD 184.59%

Maxim 16 USD

Minim 3.07 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSana Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Sana Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

49 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.